IMMU UPCOMING FEBRUARY 25th DEADLINE: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important Deadline in Securities Class Action Lawsuit; Expanded Class Period – IMMU
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Immunomedics, Inc. (NASDAQ: IMMU) from February 8, 2018 through January 18, 2019, inclusive (the “Class Period”) of the important February 25, 2019 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Immunomedics investors under the federal securities laws.
To join the Immunomedics class action, go to https://www.rosenlegal.com/cases-1484.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Immunomedics’ Morris Plains, New Jersey drug substance manufacturing facility was not in compliance with FDA requirements; (2) Immunomedics’ Quality Control Unit did not possess the authority to investigate and correct critical FDA violations occurring at the Morris Plains facility; (3) Immunomedics suffered a data integrity breach in February 2018 at the Morris Plains facility which, among other issues, included the backdating records and manipulation of bioburden samples; (4) Immunomedics’ Chemistry, Manufacturing and Control data submitted in connection with its Biologics License Application for sacituzumab govitecan was insufficient to support FDA approval; and (5) as a result, Immunomedics’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 25, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-1484.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Zachary Halper, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:Laurence Rosen, Esq.Phillip Kim, Esq.Zachary Halper, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 34th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827 firstname.lastname@example.org@email@example.com